Medical Countermeasures New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs by Global Biodefense Staff April 10, 2022
Funding News NIH Awards $3M Grant to Albany Med for Plague Vaccine Development by Global Biodefense Staff April 8, 2022
Medical Countermeasures Troubling Trends in Physician Vaccine Confidence in the United States by Global Biodefense Staff April 5, 2022
Medical Countermeasures Northwestern University Researchers Develop Nanoparticle Vaccine Platform by Global Biodefense Staff March 22, 2022
Medical Countermeasures Antibody Shows Promise for Developing Hantavirus Treatment by Global Biodefense Staff March 22, 2022
CBRNE CounterACT: U.S. Funding Early Stage Drug Discovery of Countermeasures Against Chemical Threats by Global Biodefense Staff March 21, 2022
Medical Countermeasures New NIH Study Will Follow Patients That Had Allergic Reaction to mRNA COVID-19 Vaccines by Global Biodefense Staff March 19, 2022
CBRNE ORISE Research Fellowship for Advancing CBRN Medical Countermeasures by Global Biodefense Staff March 12, 2022
Medical Countermeasures Newborn Rotavirus Vaccine Set to Save Lives by Global Biodefense Staff March 5, 2022
Industry News Appili Awarded $10M in New Biodefense Funding for Tularemia Vaccine Candidate by Global Biodefense Staff March 3, 2022
CBRNE Radiation Countermeasures: Q-3-R Alleviates Radiation-Induced Lung Inflammation and Fibrosis by Global Biodefense Staff February 27, 2022
Antimicrobial Resistance Novel Antibiotic Shows Success in Treatment of Plague and Melioidosis by Global Biodefense Staff February 17, 2022
Industry News ATCC Announces Awards from DTRA Supporting Global Health and Biodefense by Global Biodefense Staff February 15, 2022
Medical Countermeasures U.S. Purchases 600,000 Courses of Eli Lilly Monoclonal Antibody That Works Against Omicron by Global Biodefense Staff February 10, 2022
Medical Countermeasures Zika Virus Vaccine Shows Promising Results in Preclinical Studies by Global Biodefense Staff February 6, 2022
Medical Countermeasures Building Better Antivirals for the Next Pandemic by Global Biodefense Staff February 5, 2022
Medical Countermeasures First Lethal Hamster Model for SARS-CoV-2 Developed by USAMRIID Scientists by Global Biodefense Staff February 4, 2022
Medical Countermeasures Complete Protection Against Yersinia pestis by Immunization with Inhalable rF1-V10 Fusion Protein by Global Biodefense Staff February 2, 2022
Medical Countermeasures Elusys Therapeutics Finalizes HHS Contract to Deliver Inhalation Anthrax Treatment by Global Biodefense Staff January 31, 2022
Medical Countermeasures Three Doses of mRNA COVID-19 Vaccines Effective Against Hospitalizations for Omicron and Delta by Global Biodefense Staff January 21, 2022
